KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients
CHICAGO — More than 40% of patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) responded to treatment with adagrasib, findings from a phase II trial showed. Among 112 evaluable patients in the KRYSTAL-1 study, all of whom were previously treated, the confirmed objective response rate (ORR) was 42.9% with the investigational KRAS G12C inhibitor, […]